Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...
Cancer
Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...
Cowell Health Partners with AstraZeneca to Enhance Cancer Care at CIIE
Cowell Health has announced a partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) at the 5th...
Adicon Partners with Illumina to Advance Oncology Detection Assay TSO 500
China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at...
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...
Cyramza Prescribed in China for Advanced Gastric Cancer
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...
PingAn Good Doctor Partners with Roche and OrigiMed at CIIE
The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co.,...
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...
Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a...
CIIE: MET HER2 Precision Diagnosis Alliance Formed to Advance Lung Cancer Treatment
The 5th China International Import Expo (CIIE) witnessed the establishment of the MET HER2 precision...
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...
Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA
China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category...
Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study
China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products...
Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH
Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a...
Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma
China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...
Akeso Biopharma Completes Enrollment for AK112 Phase III Study
China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...
BeiGene’s Brukinsa Receives EU Marketing Approval for Marginal Zone Lymphoma
China-based biotech BeiGene Inc. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced receiving marketing approval from...
Dartsbio Licenses Potential First-in-Class BsAb DS005 to Duality Biologics
China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality...
Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA
China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...